Time to clean up the NHS

by Admin 1. December 2006 23:19
 

 

Time to clean up the NHS

On Target reports on the 2006 AfPP Congress and examines one of the event's key themes.



Jane Reid Hospital infection is an “insult to patients”, a conference audience was told at this year’s Association for Perioperative Practice (AfPP) Congress in Harrogate. Addressing the nationwide plague of healthcare associated infections proved to be a central theme at the 2006 Congress, underlined by a keynote speech that set out the Government’s strategy for eradicating this problem.

Janice Sigsworth, Deputy to the Department of Health’s Chief Nursing Officer, warned that the NHS needs to undergo a dramatic cultural change if it is to achieve its goal of ‘no avoidable infections’. In keeping with the Congress’s ‘Circles of Influence’ theme, Sigsworth said that the solution lay in collective responsibility throughout the NHS, with all staff from director level downwards playing an active role in maintaining a clean and safe clinical environment.

Sigsworth – a late-stage replacement for the Chief Nursing Officer, Chris Beasley – pinpointed the Government’s Saving Lives Programme as one of the major drivers for reversing the current trend of complacency regarding infection, and so restoring public confidence.

“The current NHS culture accepts infection as a norm,” she said. “We have become very complacent, to the point where infection has become a by-product of hospitalisation episodes. At what point does an infection become acceptable? Have we lost the will to meet this challenge? Our goal should be no avoidable infection.”

A shared responsibility

The Saving Lives Programme sets out to engage NHS staff from grass-roots level through to senior management, encouraging ownership of the problem and commitment to reducing MRSA and other hospital infections. Of course, the burden of MRSA has financial as well as health implications for the NHS. Each healthcare-associated patient infection costs the NHS £4,000–£10,000, and can adversely affect elective surgery.
Sigsworth warned that Trusts that do not have proactive measures in place to reduce infection rates will risk being shunned by patients, and that PCTs are entitled not to maintain contact with organisations that fail to put cleanliness at the top of their agenda. Subsequent questions from the audience raised some familiar issues: the conflict between hygiene priorities and economic pressures on time and resources; the lapses in safety that are widespread in NHS secondary care; the frequent differences in attitude between doctors and nurses in the theatre; and the legal and safety problems incurred through repeated use of designated singleuse products.

In answering these questions, the speaker placed consistent emphasis on “changing the culture” and the guiding role of the new Code of Practice. However, her audience may well continue to fear that when money talks, perioperative – and healthcare industry – professionals will not be heard.

Circles of influence

Visitors to the 2006 AfPP Congress could see the formidable range of tools, services and programmes that exists to tackle hospital infections and other crucial issues for today’s healthcare.


The five halls of the Exhibition in Harrogate, which this year contained over 200 exhibitors, showcased a plethora of companies whose services focused on decontaminating the NHS. In addition, companies specialising in medical devices, hospital equipment and clothing, diagnostics and healthcare recruitment promoted their services to more than 2,300 attendees, many of whom are nurses in the perioperative environment.


Over the four days of the Congress, a total of 81 speakers from the NHS and the DH addressed the AfPP membership on infection control and other key topics such as health and safety, the patient-led NHS and meeting healthcare standards. The Congress showed the circles of influence in the medtech industry and the NHS spreading and interacting.

Jane Reid, Chairman of the AfPP, was delighted with the event. “AfPP’s Congress and Exhibition again surpassed all expectations,” she said. “We have shown those working in the perioperative health sector how to extend their circles of influence, and we have provided a showcase for medical device companies to exhibit their latest products to those who purchase or influence purchasing decisions.

“Most importantly,” Reid concluded, “all the factors that make AfPP’s Congress and Exhibition the key event in the perioperative calendar combine to ensure patient care is the main beneficiary of our Congress. That is why our circles of influence are important to us.”

 

Tags:

Medtech Features

Medtech across the border

by Admin 1. December 2006 23:12

 

 

'Clusters and partnerships' in our July issue described how specialist medical technology companies are working together to promote innovation. Kay Aschaber – who has been working closely with Medical Devices in Scotland – takes a look at innovation in the dynamic Scottish medtech industry.

Scotland is beating a definitive path to the podium of world leader in medical technology, with recent successes such as the video laryngoscope and an incubator specifically designed for the transport of at-risk babies.

These outstanding achievements are fuelling the passion of the Chief Executive of Medical Devices in Scotland (MDIS), Kevin Wilson. The past month alone has seen Kevin play a bagatelle circuit from Scotland to Minnesota, Florida and Dusseldorf – all in the name of Scottish medical technology. With 80 member companies in his charge, Kevin Wilson’s territory covers a rich and vibrant research and development base. Notable hotspots include imaging, ophthalmics, orthopaedics, cardiovascular instrumentation and implants. During the last five years the life sciences sector in Scotland has doubled in size, and one of the most prominent areas of growth has been medical technology development.

“There is a particular drive from the companies in Scotland to punch well above their weight,” Kevin noted. “One of the country’s youngest and most energetic companies is Lightweight Medical, which has not only found a niche in neo-natal transportation but has interwoven its environmental awareness into its planning and the strategy of all its product designs.”

New kids on the block

Neil Tierney and Neil Farish, the founding directors of Lightweight Medical Ltd in Glasgow, have built a directing team of five and a design team of nine. They have licensed out their first groundbreaking design for a new generation of portable incubators for premature babies: the neo-capsul™.

The company was set up by the duo in their final year at university in 2003. Their first creation was the world’s first incubator design intended for transportation. They spent the next three years carefully researching and developing the product in close consultation with NHS clinicians.

Incubators have suffered from a lack of development over the past 20 years. After identifying this gap in the market, the two designers spent many months in ambulances and emergency rooms, determining what was needed in a new-generation incubator. With the company’s focus on market opportunity, matched with their IP, the team successfully developed the neo-capsulTM – which is not only a first on the world market, but has been designed to ensure that, where possible, every component can be reused or recycled at the end of its life.

As well as the drive to fit a niche in the medical technology market, Tierney and Farish displayed an astute business sense. Their signing of a licensing agreement with ParAid Medical Systems has brought the design into the reality of manufacturing and distribution. This licence is only the start of the multiple innovation portfolio that the company is geared to deliver over the coming years.

The thread of innovation

But it’s not only the newcomers who are hitting hard. Many well-established medical device companies in Scotland have a rolling programme of innovation to meet the accelerating sophistication of the medical field.

A prime example is West of Scotlandbased vascular graft manufacturer Vascutek, which produces over 1000 grafts a week designed to patch diseased or damaged arteries in hospitals around the world. In 1979, the management at J&P Coats (a household name in thread production) had the intuition to set up a ‘New Ventures’ section, consisting of textiles R&D experts and two bio-engineers. Noting the success of this innovative team, J&P Coats backed it with risk capital to buy machinery with the potential to take the company to new heights. That risk bore the fruits of a new medical device company, known today as Vascutek, which turns over in excess of £35million and is Europe’s market leader in large-diameter textile-based vascular grafts.

Having initiated a new generation of vascular graft design, the company went on to produce a unique method of sealing grafts that removed the need for the surgical pre-clotting process. The new method saved surgery time and improved safety.

Today, Vascutek is owned by Japanese medical technology giant Terumo Corporation, and most of its 350 staff members are employed at its Glasgow plant near the airport – where the Research & Development facility still resides, along with its President Dr Roshan Maini, who was one of the original bio-engineers back in the ‘New Ventures’ years at J&P Coats.

“We’ve learned much along the way,” said Dr Maini, “but one of the most important aspects of that journey has been to understand and develop true customer service. We have the knowledge of the medical sector, the close liaison with our customers and the clear ideas that keep us ahead of the game.”

What is MDIS?
Medical Devices in Scotland (MDIS) represents 80 companies in the medtech sector. It was established to support and strengthen the medical device industry in Scotland by developing the partnerships between the Scottish NHS, academia and industry to assist the commercialisation of ideas.

The aims of MDIS are to:

•Act as a catalyst to congregate members, network and share knowledge through partnerships.
•Represent the views of the medtech industry to UK and local governments and the NHS.
•Build awareness of the industry in general and the many businesses operating within it.
•Match companies for potential collaborative work.
•Help develop sustainable critical mass in the medical device sector in Scotland.
•Help attract UK and world graduates to the field by publicising the innovative nature and success of the Scottish medical device industry.
•Assist in identifying funding sources.
•Promote the world-leading technologies of Scotland internationally. For more information, visit www.mdis.org. MDIS is a member of MediLink UK (www.medilinkuk.com).


The company’s four Queen’s Awards for Export and one for Technical Achievement are evidence of these qualities, and a true reflection of the highlyskilled and sustainable workforce that drives the company.

World first in intubation technique

Another rising star reflecting the inventive nature of the medical devices sector in Scotland is Aircraft Medical Ltd. After launching the McGrath® Series 5 portable video laryngoscope (the ‘McGrath’) this year, Aircraft Medical Ltd signed a five-year distribution deal for the US that could earn the company more than £27million. Created by Chief Executive Matt McGrath, the new laryngoscope is set to become essential for operating theatre departments and other critical care units. It allows tracheal intubation with a view of the patient’s airway.

Previous laryngoscopes were based on a 1940s design and did not have this crucial method of imaging, which now enables the operator to position the tube more accurately and safely.
McGrath laryngoscope
The laryngoscope’s initial success has been marked by a series of design and industry awards for the company, including one from the Audi Design Foundation as well as Scottish Enterprise and the Scottish Executive. The McGrath is the result of international research involving over 1,500 medical professionals, and is recognised to be “the most significant advancement in laryngoscope design since the 1940s” (Dr G. Enever, Royal Victoria, Newcastle). Aircraft Medical is now widely recognised as a leader in miniaturised imaging technology for medical product design.

With initial orders from NHS trusts already on the company accounts, Aircraft Medical’s portable laryngoscope has made a sizeable impact on the life sciences community in Scotland – and its design and engineering capability are rapidly becoming a focus for medical device innovation around the world.

Footprints in the USA

These are only a sample of the medical device companies in Scotland that show similar drive and charisma. Kevin Wilson and MDIS are determined to give Scottish companies maximum exposure both at home and abroad.

In the last few years, Wilson has built up stronger links with the US through liaison with Medical Alley in Minnesota, which pulls the diverse areas of the American healthcare industry together to discuss and develop creative, proactive and problem-solving approaches to the key challenges and opportunities facing the industry.

Kevin noted: “Medical technology companies in Scotland are not small in ideas, and it is an international forum of discussion and development, such as Medical Alley, that they need to move forward.”

Medical Alley, headed up by CEO Don Gerhardt, has already seen great prospects in Scottish medical device ventures and the skills that drive them. During a recent DTI Globalwatch mission, it was noted that Scotland was already on the Minnesota radar for its creativity, and that dialogue with SMEs had already begun.

“Many Scottish companies have the X Factor of medical technology, and we are determined to ensure that the world market realises their capabilities.” Kevin Wilson, Chief Executive, MDIS

MDIS is targeting specific collaborations through relevant industry organisation counterparts such as Life Sciences Alley in Minnesota, Florida Medical Manufacturers’ Consortium and Boston’s MASSMedic. “By bringing US and Scottish medical technology companies together, we can learn from each other and help create better products to meet tomorrow’s needs,” Kevin Wilson said. “It is essential that the US companies working in the medical technology clusters are aware of the skills and capabilities that Scottish companies can contribute.

“Many Scottish companies have the X Factor of medical technology, and we are determined to ensure that the world market realises their capabilities.”



Kay Aschaber is a consultant working in collaboration with MDIS to examine and highlight the range and depth of the medical device industry in Scotland.

 

Tags:

Medtech Features

The safe road TO SALES

by Admin 1. December 2006 23:11
 

 

“It's totally safe” is a poor use of the selling power of product safety in the medical devices field. Saba Hinrichs and James Ward explain how product safety information can empower the sales process.

In this age of rapid change, with converging technologies and a global marketplace, it is imperative that the medical device industry’s approach to procurement does not slip out of date. Given the increasing impact of product ‘value’ on purchasing decisions, sellers need to convince their buyers of reduced risk to the patient, increased safety, improved quality of life, and the long-term cost savings that some new innovations can bring.

But what role does procurement have to play in improving patient safety in an environment where the ‘right price’ is king? And how can medical device sales professionals make use of product safety data, and thereby make a positive contribution towards long-term benefits and safety to patients?

Purchasing for patient safety

Patient safety is steadily being raised further up the agenda for the Department of Health and the NHS Purchasing and Supply Agency (PASA), exemplified by their adoption of the term ‘Purchasing for Safety‘. Research into patient safety has been growing since the early 1990s, and the findings by the National Patient Safety Agency (NPSA) have shown the importance of good design practice in the improvement of safety.

Traditionally, patient safety has been measured through a count of medical device errors. The causes of these errors fall into several categories, such as design, environment of use, education/training, communication and management of equipment within the hospital. It has been shown that in episodes where harm has been incurred, a significant percentage of the errors can be attributed to the design of the device. Also, a significant proportion of errors can be attributed to medical professionals not using the right device in the right environment in the right way.

By identifying devices for their hospitals, purchasers can play a significant role in improving patient safety. Equally, those selling the devices can point out their safety features and so encourage purchasing for patient safety. The diagram on the right illustrates how the patient safety features of medical devices can be identified by capturing the requirements of users and articulating these as guidelines to promote purchasing for patient safety. As they are central to the introduction of devices into the healthcare setting, purchasers are also in a position to communicate user requirements back to designers – thus encouraging design for patient safety. The potential outcome is a ‘virtuous circle’, with both patient benefit and safety being improved.

From price to value

Recent changes in NHS procurement, as initiated by the HITF report, have created the opportunity to offer more integration of clinicians, purchasers and suppliers into a well-informed network. Organisations such as the Centre for Evidence-based Purchasing (CEP), Collaborative Procurement Hubs (CPH), Healthcare Technology Co-operatives (HTC), the National Innovation Centre (NIC) and other arm’s length bodies could help to address ‘value’ criteria in purchasing medical devices, and their initiatives will be worth watching. The DHL/Novation purchasing and distribution deal may also have major implications for procurement.

As the ABHI’s Director General John Wilkinson commented in On Target (June 2006), “there is, through the HITF process, a growing opportunity to get buyers, managers and clinicians constructively engaged in the procurement of products that offer best value rather than lowest price; and the message about redesigning clinical pathways and processes around opportunities afforded by new technologies will get through more broadly.” However, problems that are still limiting this approach include:

•A lack of common understanding across the NHS in defining patient safety.
•The remoteness of the user from the designer and purchaser.
•Errors caused by the design of the product or lack of knowledge of the system in which the product operates.
•Lack of influence of national
•Limited training of procurement staff.
•Lack of need-driven procurement.
•Barriers caused by current purchasing drivers, such as decisions driven by immediate cost.
•The complexity of the current procurement system (though the changes put in place since the HITF report show promise).

Questions to be answered

Given this changing landscape, some of the key questions that need to be addressed by device suppliers are:

•How can we identify and then articulate what features of a device bring improved patient safety?
•How can we convince purchasers to invest in the long-term benefits that a product can bring, rather than basing purchasing decisions solely on immediate price?

Questions about characterising device safety have been raised in other safety-critical sectors, such as the defence, aviation and railway industries, but many lessons learned from these have yet to reach the medical device industry. Medical device features that characterise safety could include: proof of the product in use, product lifespan (actual and ‘situationdependent’), cost of use (both short- and longterm), complexity, consumables required, connectivity to existing equipment in the hospital.

Sales professionals should make use of demonstration and documentation, have background knowledge of the product ‘in use’, and be aware of the long-term service and maintenance that are available with the product.

However, assessing both the financial and the health value of a product can be tricky. Depending on who is asking the question, ‘value’ can mean different things to different stakeholders.

Involving the supply chain

Such questions form part of the challenge of current research in the Engineering Design Centre. Through dialogue with key stakeholders such as PASA, NPSA and CEP and studies with purchasing departments at NHS trusts, some of these complex issues will be addressed. The key objectives are to:

•Engage all stakeholders to raise awareness and build the knowledge base around patient safety.
•Develop an understanding of the current procurement processes for medical devices.
•Identify the features of a medical device that characterise patient safety.
•Develop a model or framework of purchaser requirements.
•Raise awareness of this model through the supply chain, including sellers.

This project stems from the work of the Design for Patient Safety Initiative, whose recommendations included a systems-based, user-led approach to improving services across the NHS. For this, both the design of the products or services and the healthcare system in which these products are used need to be orientated towards maximising patient safety.

Involving the supply chain
Applying this approach to medical devices in particular requires us to look at the role of procurement, and then to address the whole lifespan of the device from its design to its use in clinical practice.

This project is still in its early stages, and we would welcome your input and support in further discussion. If you would like to be involved in the study and help identify what features of the devices you are selling characterise its safety and benefit, please get in touch.


Saba Hinrichs is a research student at the Engineering Design Centre (EDC) at the University of Cambridge, supervised by Prof. John Clarkson. She can be contacted at sh467@cam.ac.uk. Dr James Ward is a Senior Research Associate at the EDC.

 

Tags:

Medtech Features

Building Bridges

by Admin 1. December 2006 23:09
 

 

Does your role as sales professional end with closing the sale? If so, you may not get that far more than once per customer. Eddie Merrick explains what customer service means to him as an NHS Theatre Manager.

All relationships, whether private or professional, are built on trust. Trust between companies and healthcare organisations is a two-way experience. A lack of mutual trust leads to a below-par concept of the customer service a company provides.

In many organisations, company representatives rely on a ‘hard sell’ that refers exclusively to product advantage – with little regard for building a productive standard of service to achieve long-term customer satisfaction.

In my experience of working in ophthalmic healthcare, a great deal of communication is needed to gain an effective service. This is primarily true of the larger organisations – however, small businesses are not totally exempt. Customer care and satisfaction often seem low-priority issues. Many healthcare sales professionals regard customer care as a cosmetic exercise – and I have found this all too evident, often to the detriment of the service I provide to patients.

Open your eyes

The NHS constitutes a highly-charged and competitive market, with cost predominantly at the top of the agenda. A vast array of companies produce, market and sell medical devices. As customers, we develop an attitude towards the company and the representative based on previous experience and professional judgement. We need to look not just at cost, but also at reliability, quality, customer service and communication expertise – the things that encourage good working relationships, creating a joint business strategy between the customer and the healthcare company.

Over many years, the NHS has developed a large organisational team to manage interaction with supplier companies and their representatives. Strategies and training for all key staff are now a major part of developments in the NHS for working in partnership with healthcare suppliers.

Where possible, I try to build on the strengths of companies that have already proven their success in delivering the kind of service necessary to maintain a high level of satisfaction to me as a healthcare provider. However, where companies have built a firm foundation and business relationships with their customers, too many then reduce their services and customer care. This gives a lifeline to their smaller rivals, who often provide excellent service and reliability beyond their larger counterparts’ more isolated approach. Companies that have influenced past service requirements often lack continuity and communication with their existing customers.

One has to recognise this ‘diminishing returns’ tendency, which becomes evident all too quickly. To ensure consistency while maintaining service demands, a strong individual company assessment is logged within my organisation to provide confidence and stability. Company representatives can often play a major role in this assessment, being the crucial link in service demand.

Take the money and run

However, this strategy can sometimes prove to be fragile. Companies often do not work hand in hand with their representatives, and this can prove highly damaging to their customer relationships.

A recent example of this was a major piece of equipment that we purchased for approximately £65k.The installation date had been arranged three months in advance. However, the company had not liased with its European Supply Division to arrange the delivery of this equipment – thereby, at one point, putting the whole installation process at risk, which could have resulted in the cancellation of patient and theatre time over a two-day period. Only after the intervention of both myself and the company engineer were we able to proceed as planned, quite literally with only hours to spare. With the equipment installed, only one full day was available for teaching and demonstration purposes for the staff – there being no company representatives available to continue with training and back-up support on site until a further three weeks had gone by.

I feel that this attitude and approach leaves one with the impression: “You purchased this equipment – now it’s up to you to make the best of the situation!” No direct apology has been made to myself or my organisation for the total lack of support we experienced over the first few weeks after installation. I highlight this as an example of the problems I have encountered, but it is by no means unusual. The company is wellknown and one of the largest in its area of the healthcare industry.

I did ask the company concerned whether they had a customer evaluation procedure on equipment or services provided by them. The response was: “We don’t normally request information from our customers.” How can bridges between company and customer be built without this vital feedback tool? If any future service might involve this company as provider, an alternative supplier in the field will inevitably be considered.

Someone who cares

Customer care is an important principle in the NHS. Arguably, the expectations go beyond the reality. However, great strides have been made in the last few years by both large and small supplier companies to improve their image in terms of customer care. My expectations are mostly met, and I can directly list my requirements as regards customer care when talking to a representative.

My most important issue is communication – a principle that companies and representatives usually regard with professionalism and respect. The advantage of the ‘procedure’ systems that we operate in the NHS is that we have control and the system is transparent to all. Everyone knows their responsibilities and acts accordingly. Many customer care issues run ‘silently’, as they are designed around normal working practice. The majority of our concerns are parallel to those of our suppliers, making it easy for all those involved to recognise the priorities.

Most companies now implement a comprehensive standard service to their NHS customers to incorporate stock control, a stock recall service and, where appropriate, a decontamination certificate and traceability service. This is a general policy of best practice governed by the customers themselves. And while the sales representative is not directly responsible for all aspects of customer service, good communication by the representative with both the customer and the company will help to build strong bridges.

In many organisations, company representatives rely on a 'hard sell' that refers exclusively to product advantage – with little regard for building a productive standard of service to achieve long-term customer satisfaction.

Customer care relationships are now steadily improving, with a few of our local companies willing and able to deliver on a request basis (when essential) within one or two hours. Companies further away can, and often do, supply within a 24-hour period with no carriage costs or penalties being incurred by their customer. For this comprehensive level of service to be available, a great deal of communication must already have been achieved by both the company and the representative.

Across the great divide

Healthcare businesses and their NHS customers often have different objectives and business strategies. Mutual understanding is not always straightforward – but with such an understanding in place, a deeper relationship can generate a ‘one to one’ solution that incorporates loyalty, operational productivity and profitability. In order to deliver goods and do business, you first need to build bridges.


Eddie Merrick is Eye Theatre Manager at the Royal Bournemouth Hospital.

 

Tags:

Medtech Features

Innovation rewarded at Prix Galien 2006

by Admin 1. December 2006 05:00

The 2006 UK Prix Galien sprung a surprise this year, with three companies awarded medals for pharmaceutical innovation. Pf reports on this year’s prestigious awards.

GSK and Novartis jointly took the main Prix Galien Award for Rotarix and Xolair respectively, while Genzyme’s Myozyme received a special Prix Galien medal as an orphan drug.

Prix Galien 2006










The prestigious award was presented by Shadow Secretary of State for Health, Andrew Lansley MP, at a packed ceremony at the House of Commons. The 2006 competition saw a 40% increase in entrants from the previous ceremony in 2004. In fact, six of the 14 nominations were oncology treatments, reflecting the management of cancer as a key NHS priority.

The winners were announced by Professor Sir Michael Rawlins, Chairman of NICE and head of the Prix Galien judging panel. Professor Sir Michael began by acknowledging the achievements of all participants, and underlined the significance of the Prix Galien. “The Prix Galien is about honouring excellence in pharmaceutical research and development, and it is about recognising the contribution that new medicines make to the public health,” he said. “It represents a pinnacle of achievement for the men and women who are committed to curing disease and improving health by bringing us those medicines. The judging panel has been impressed by the creativity, innovation and scientific rigour that have gone into these new medicines. In their own way, every one of these medicines is having a significant impact on clinical practice in the NHS, and on the health and quality of life of thousands of patients.”

Special award for Orphan Drug

Genzyme earned its special Prix Galien medal for Myozyme, the first enzyme replacement therapy to target a neuromuscular disorder. Classified as an ultra orphan drug, Myozyme provides a treatment option for Pompe Disease. Orphan conditions affect a very small number of patients, and many are currently untreatable. Although they have a low prevalence, collectively orphan conditions create a significant health problem. It is estimated that around 6000 defined orphan diseases currently affect about 30 million EU citizens. For orphan diseases that are potentially treatable with medicines, pharmaceutical manufacturers face a number of complex problems, including concerns with regard to limitation within the market and length of time required to develop the compounds to commercial products.

“Genzyme has shown continued commitment to meeting unmet medical needs within the field of orphan diseases and the clear clinical improvement shown in patients affected by this devastating disease is a remarkable achievement,” said Professor Sir Michael. “Myozyme provides a treatment option for Pompe Disease, previously treated only in a palliative or supportive manner. This was an outstanding entry in a very difficult area.”

Rotarix and Xolair

As in 2004, the coveted main Prix Galien prize was awarded jointly to Rotarix and Xolair. GSK’s Rotarix, a live attenuated human rotavirus vaccine, offers a very high protection rate against severe rotavirus gastroenteritis. Rotavirus infects virtually every child in the first five years of life regardless of race or socioeconomic status.

“The panel was impressed that GlaxoSmithKline has overcome the safety issues associated with the development of earlier Rotavirus vaccines to produce a safe and effective vaccine tested in over 60,000 children worldwide,” said Professor Sir Michael.

“The heterotypic protection (against wild-type strains) as well as homotypic protection (against the vaccine strain) could greatly reduce morbidity and mortality associated with this disease, whilst being cost-saving to society.”

Prix Galien 2006










Xolair, developed by Novartis Pharmaceuticals UK Ltd, is a first in class treatment specifically developed to target Immunoglobulin E (IgE), the underlying mediator of allergic response in severe persistent asthma. The panel praised the innovation demonstrated through Novartis’ novel targeting of IgE: “Xolair has shown very clear efficacy benefits for patients who have exhausted their therapeutic options and who are under constant threat of exacerbations,” said Professor Sir Michael.

The remaining nominations for the 2006 UK Prix Galien were:

Alimta (Oncology) Eli Lilly
Alvesco (Asthma) ALTANA Pharma UK
Aromasin (Oncology) Pfizer
Avastin (Oncology) Roche
Erbitux (Oncology) Merck Pharmaceuticals
Lyrica (DPN) Pfizer
Movicol Paediatric Plain (Laxative) Norgine
Moviprep (Bowel cleansing) Norgine
Protelos (Osteoporosis) Servier Laboratories
Tarceva (Oncology) Roche
Zevalin (Oncology) Schering Healthcare



The Prix Galien’s UK franchise is owned by The WG Group. For further information on the Prix Galien, visit www.wg-group.co.uk and click on Prix Galien.

Tags:

Features

FROM THE FIELD

by Admin 1. December 2006 05:00

Tim, our representative speaking ‘from the field’, gives his light-hearted angle on an issue that provokes strong feelings in all medical sales professionals: age discrimination.



Age discrimination

WHICH IS MORE IMPORTANT, the exuberance of youth or the experience that comes with age? This is a question that is getting a lot of interest at the moment. Youth is wasted on the young, but then I suppose that experience is wasted on the senile, so the answer is that both are important. How often have you heard people say ‘I wish I’d known what I know now when I was younger’? We seem to live a cruel existence in which we only find out what we want to do when we are no longer able to do it.

If we translate this to the work environment, we can see that we need a mix of employees. New ideas and enthusiasm combined with sage advice from those who have learnt from their mistakes. I know that older people can have new ideas and younger people can be wise beyond their years, but typically a mix of ages will provide a good sample of relevant skills. If you don’t agree I would keep quiet because age discrimination is about to become illegal.

Older workers suffer from various types of discrimination. They may find it hard to get work. They may be passed over for promotion or denied access to training courses. This seems illogical, as older employees could have skills which inexperienced workers may need to achieve through expensive training or years of learning on the job. It is surely not a bad thing to know too much, unless you are a spy or a member of the criminal underworld, and if you are either of these things you are unlikely to work for a pharmaceutical company.

There is no biological reason that when you have a certain number of years behind you all your drive and desire should go. Isn’t life supposed to begin at forty? And I’m sure wise words are supposed to come from the mouths of babes. Children can’t drive though, so employing them as medical reps is out of the question. Clearly some sort of age discrimination has to remain. We’re not about to start sending schoolkids down coalmines again, even if it would stop them hanging around outside my local co-op.

Age should not be important. The older I get the more I see the real truth of this. If you are thinking of discriminating against older people remember that your turn will come. How do you want to be treated in future years?

I hope all this makes sense. If it doesn’t you can let me know by emailing tim@healthpublishing.co.uk If there is a topic you would like me to cover then contact me. Similarly if you have any comments about an article then I would love to hear from you.

Merry Christmas and a Happy New Year!

Tim (tim@healthpublishing.co.uk)

 

Tags:

Features

Pharma enters a new age: assessing age discrimination

by Admin 1. December 2006 05:00

New age discrimination regulations came into force on October 1st, presenting the pharmaceutical industry with what employment law specialists have described as one of the most far-reaching pieces of legislation to affect the workplace in the last 30 years. Pf looks at the new regulations and what they mean for you and your employer.

IN SIMPLE TERMS, the new age discrimination measures do exactly what they say on the tin. They make it illegal for employers to discriminate against employees because of their age – this not only concerns recruitment issues but also areas such as vocational training, the award of professional qualifications and trade union membership.

According to Jonathan Bruck of B P Collins solicitors, the legislation may call for extra caution in some surprising areas: “The measures cover victimisation or harassment, so sending joke ‘over the hill’ birthday cards to staff may be unwise! Whether you view the new regulations as excessive or an inevitable and necessary piece of protective legislation, if you are an employer, you should certainly sit up and take note: there is no limit on the compensation available to an aggrieved employee who succeeds at a tribunal.” So what do the Regulations mean? It is unlawful for an employer to:

• treat staff less favourably on grounds of age in its recruitment methods, in refusing to offer employment, in its terms of employment, in respect of promotion, transfer or training opportunities, or in dismissing an employee
• indirectly discriminate by applying a policy or work practice (which otherwise applies equally to all staff) and, by so doing, place an employee of a particular age group at a disadvantage when compared to other employees of other age groups.

Such treatment may be allowed if it is a "proportionate means of achieving a legitimate aim", but until case law can provide specific guidance, relying on this justification could be risky. The Regulations also provide for circumstances in which retiring an employee could amount to discrimination and/or unfair dismissal. The compulsory retirement of an employee before the age of 65 is now unlawful unless it can be objectively justified, although a dismissal by reason of retirement over the age of 65 would not constitute unlawful age discrimination. However, employers must be sure to follow carefully the procedures laid down in the Regulations, which include providing the employee with between six and twelve months notice of dismissal.

Employees have the right to ask to work past retirement age and employer and employee need to follow a set statutory procedure in dealing with such requests. Failure to do so will, in certain circumstances, make a dismissal automatically unfair. Significantly, the age limit on bringing a claim for unfair dismissal and entitlement to statutory redundancy pay has been removed.

In Ireland (where age discrimination provisions were introduced in 1998), age discrimination was the third most commonly cited ground of discrimination after gender and race in 2004, with over 25% of equality cases including age as a ground. Many believe that the UK will be impacted in the same way.

The measures are tipped to have huge significance on the employment market, particularly as the latest projections from the Office of National Statistics indicate that a third of the labour force will be over 50 years of age by 2020. Patricia Davies, Marketing Manager, GBS Corporate Training, believes that many companies remain ill-prepared for the new legislation. “HR departments in all sectors need to understand how the legislation will affect their workforce, and how they can ensure they take the lead on these issues,” she says. “The Government's legislation highlights the growing economic worth of an older workforce. With the average UK life expectancy now approaching 80, organisations must recognise that older employees often have the same drive and enthusiasm as younger employees, complemented with a wealth of experience and knowledge. It is particularly important to know in what way individual job profiles can be changed to take into account the different ability levels of older employees.” Jonathan Bruck fears a wave of US-style litigation should companies fail to respond. “Time will tell whether the Regulations will mark the beginning of a ‘new age’ for employee rights in this country, but employers must now ensure that their policies and practices are compliant, to minimise the risks of a costly ‘coming of age’.”

What the regulations mean to you

Am I protected against discrimination because of my age? Yes. You are protected against direct and indirect discrimination. It is unlawful on the grounds of age to:

• decide not to employ you
• dismiss you
• refuse to provide you with training
• deny you promotion
• give you adverse terms and conditions
• retire you before your usual retirement age without justification.

Is it ever legal to discriminate against someone because of their age? There are limited circumstances when it is lawful to treat people differently because of their age. For example, it is not unlawful to discriminate on the grounds of your age:

• if there is an objective justification for treating people differently – for example, it might be necessary to fix a maximum age for the recruitment or promotion of employees (this maximum age might reflect the training requirements of the post or the need for a reasonable period of employment before retirement)
• where you are older than, or within 6 months of, the employer's normal retirement age, or 65 if the employer doesn't have one, there is a specific exemption allowing the employer to refuse to recruit you.

Do I have the right not to be harassed because of my age? Yes. Harassment includes behaviour that is offensive, frightening or in any way distressing. It may be intentional bullying which is obvious or violent, but it can also be unintentional, subtle and insidious. It may involve nicknames, teasing, name calling or other behaviour which is not with malicious intent but which is upsetting. It may be about the individual's age or it may be about the age of those with whom the individual associates. It may not be targeted at an individual(s) but consist of a general culture which, for instance, appears to tolerate the telling of ageist jokes.

Who is responsible for harassment? Employers may be held responsible for the actions of their employees – as well as the employees being individually responsible. If you harass someone you may be ordered to pay compensation. When deciding if you have been harassed, how you feel about what has happened to you is very important.

ACAS Examples

•Whilst being interviewed, a job applicant says that she took her professional qualification thirty years ago. Although she has all the skills and competences required of the job holder, the organisation decides not to offer her the job because of her age. This is direct discrimination.
•A job applicant can make a claim to an employment tribunal, it is not necessary for them to have been employed by the organisation to make a claim of discrimination.
•A young employee is continually told he is 'wet behind the ears' and 'straight out of the pram' which he finds humiliating. This is harassment.
•An employee has a father working in the same workplace. People in the workplace often tell jokes about 'old fogies' and tease the employee about teaching 'old dogs new tricks'. This may be harassment on the grounds of age, even though it is not the victim's own age that is the subject of the teasing. For more information on the new laws, visit www.acas.org.uk

Tags:

Features

An Outstanding Performance

by Admin 1. December 2006 05:00

Star of the Pf Awards 2006, Christine Clapham came away with both the Career Representative and Outstanding Performer award. We caught up with Christine to ask how her temporary celebrity status has impacted her career and what advice she would offer to would-be winners entering the awards this year.

How did it feel to win, not only one award, but two?
I was so pleased to have won, both for myself and for Abbott. I was totally shocked and surprised as there were such a large number of quality entrants.

How would you describe the experience of entering the awards?
It was such a well-organised day. Everyone in charge was helpful and friendly, trying their best to reassure people. It was nerve-racking but on reflection a very enjoyable day. I did learn something about myself however, I did not realise just how competitive I am! I really did want to win.

If you were giving your ‘Oscar’ speech, who would you thank?
I would have to say a big thank you to my Regional Manager Alice Green ,as she cajoled me into taking part. Also to all the Senior Managers who were present at the Award Ceremony supporting the Abbott candidates. Not forgetting Pf for organising such a prestigious and memorable event.

What advice would you offer to candidates entering the 2007 awards?
Spend time preparing. For the telephone interview you will have to answer a number of questions in a call that could last up to twenty minutes. If you are lucky enough to get through to the next stage you will be sent a briefing pack explaining the sort of presentations you will be expected to do on the assessment day. Be relaxed and be yourself, but most of all enjoy the day and the experience.

How has winning these awards affected your professional and personal life over the past six months?
An oustanding performance Professionally, the awards have given me confidence in my own abilities as a Career Representative. The awards have been recognised by Abbott through many internal communications and I was presented with the Abbott Board of Management award at the last Conference. Personally, it has been wonderful to receive accolades from my colleagues within Abbott and also from fellow representatives from many other Pharma Companies, some of whom I have never even met before.

What do you enjoy about your role and what do you find frustrating?
I enjoy being a Medical Sales Representative because everyday is a new challenge, everyday is different. No matter how well you know the customer, their needs can change overnight, so you have to be able to adapt and think on your feet. Customers should be treated with the same professionalism and enthusiasm no matter how often you call on them. What is frustrating is the increasing workload that all our customers are experiencing in the NHS, making it difficult for us to access them.

Who inspires you, professionally or otherwise?
People who have the ability to think outside the box and bring new innovative ideas to the table, thereby increasing success.

What qualities do you feel are needed to be successful as a ‘career representative’?
Being able to develop relationships is the very nature of the job, but as you are not able to see the results immediately, you have to learn to be patient. When you have a bad day and it is raining, just try and be positive. You have to know what you want to achieve and what your priorities are to succeed and believe that you can do it. Your confidence can take a lot of knocks during the working day, so you have to believe that you have ability to be successful without being arrogant. Having a good sense of humour helps too!

Do you regret any of the career decisions you’ve made?
I have no regrets whatsoever. The role of the MSR is one of the most important roles in the company and something I still find rewarding and challenging.

What would you say was the best decision you ever made?
Making the decision many years ago to stay in this role and not to be tempted to pursue another path.

Will you be returning to the 2007 awards to defend your title?
2006 has been the pinnacle of my career in winning two of the top awards within the pharma industry. I feel someone else deserves to enjoy the experience.

Tags:

Features

Closing Ranks

by Admin 1. December 2006 05:00

Is the writing on the wall for one-to-one detailing?

GP adherence to PCT policy has occurred far faster than expected. Pharma companies need to stop paying lip service to the changes in the NHS and get a real insight into prescribing behaviour if they are to attain any value from sales and marketing activity, insists Gareth Thomas, managing director, Cegedim UK.

THE WRITING has been on the wall for the traditional representative/GP detail visit for some time, and pharma companies have begun to experiment with new forms of communication such as the practice level ‘lunch and learn’. But few pharma companies could have expected prescribing behaviour to change quite as rapidly as it has done. Despite low key efforts to communicate in different ways with prescribing influencers across the NHS, there is little evidence that these companies truly appreciate the true extent of the changes in prescribing behaviour.

Yet according to figures from Cegedim, 70% of GPs are already prescribing within the guideline of the practice. The information, compiled from InfoPharm prescription data, reveals an extraordinary shift in behaviour that seems to have taken the industry by surprise.

Given the pace of change, is there really any point in undertaking the one-to-one GP visit any more?

Changing Behaviour

Is this shift in behaviour really a surprise? PCT guidelines now provide GPs and practices with less and less opportunity for individual decision making. Since PCTs are increasingly demanding the prescription of generic rather than branded drugs – and withholding points for those who fail to adhere to specific targets – perhaps the pharma companies should have been more prepared.

At this rate, it is estimated that 99% compliance to PCT guidelines will occur within five years. While pharmaceutical companies have realised that influence networks are changing, how much radical change has really been achieved? Is the appointment of key account managers really going to be effective or is it just paying lip service to the changing prescribing behaviour across the NHS?

There is no going back. And any pharma company wanting to retain market share needs to face up to the reality of these changes and the real effect they are having on sales force effectiveness.

What Value?

There is obviously no value to be gained from targeting one-to-one visits that deliver the traditional product message to the 70% of GPs now complying with practice guidelines. There is, therefore, a pressing need to improve targeting and focus representative efforts on those 30% of GPs not adhering to PCT policy.

But it is also critical to understand the influence of each group in the core market to assess just how seriously the changes in behaviour will affect market demand. Are the 70% high or low prescribers? And the 30%? Are those following their own prescribing rules more or less likely to see representatives? Is there a correlation across specific PCTs or regional areas?

Furthermore, 70% of prescriptions are now for generic drugs. This has a serious implication for the pharmaceutical sector, which must now focus attention on making branded products the top choice should generics fail to suit a patient. Without this detailed understanding of a fast changing marketplace, pharma companies will be wasting valuable sales and marketing resource. If representatives are to be effective in the new NHS they need real time access to up to date information on local prescribing habits to ensure message relevance.

Targeting and prioritisation is essential. While the independent GPs may be in decline, they remain an important route to market in the short term. Just where are those 30% still eschewing the PCT path? Identifying and targeting these individuals remains critical. Indeed, it is possible that some of these GPs may not have previously been on the pharma company’s priority list. In this new environment, there could well be an opportunity to forge important new relationships – but only if the prescribing information confirms their potential value.

New Information

The detailed information now available to pharma companies is enabling extraordinary levels of analysis and profiling. This includes patient switching data from Talis, which demonstrates trends in support for PCT directives and is critical for any pharma company either at risk of switching or looking to maximise switching opportunities.

Combining this information with prescription data provides the detailed understanding of the local health economy that will be critical in determining the message for each representative visit – whether that is to a single GP or at practice level.

If, for example, a practice shows a high degree of compliance with PCT guidelines and a strong commitment to generic products, the message needs to focus heavily on an alternative to the traditional product sell. These can range from the role of branded products in reducing side effects in specific patients to co-promoting a product’s benefits when prescribed in conjunction with other branded or generic drugs – such as to combat nausea induced in cancer treatment.

Indeed, as prescribing compliance becomes standard behaviour, GPs and practices will increasingly expect this level of insight from pharma companies to support specific patient cases. For example, providing information to help a GP determine the best treatment for patients who either react badly to specific generic products or are struggling with the side effects of multiple drug interactions will become increasingly important.

Critically, this information provision must be delivered via multiple communication channels. Organisations can use the direct sales force to create the relationship and build the co-promotion message, for example, but back this up with online support in response to specific GP queries on demand.

Taken By Surprise

The speed of change in prescribing behaviour has undoubtedly been a surprise. It has given pharma companies little time to introduce new models for direct GP and practice based communication. But it is clear that small scale moves towards the group ‘lunch and learn’ and the occasional e-detail need to be rapidly expanded to support this extraordinary shift in attitude. The market is changing faster than most companies realise. It is those organisations that combining excellent, up to date information with a flexible multi-tiered model, that will be best placed to ensure sales and marketing spend continues to deliver value.

Gareth Thomas is Managing Director of Cegedim UK. Cegedim is a European leader in the production, use and distribution of data and services linked to medical information and CRM activities. For more information, contact Cegedim UK at www.cegedim.co.uk

Tags:

Features

TextBox

Tag cloud

Calendar

<<  May 2013  >>
MoTuWeThFrSaSu
293012345
6789101112
13141516171819
20212223242526
272829303112
3456789

View posts in large calendar